These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21748710)

  • 21. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.
    Chilcott J; McCabe C; Tappenden P; O'Hagan A; Cooper NJ; Abrams K; Claxton K; Miller DH;
    BMJ; 2003 Mar; 326(7388):522; discussion 522. PubMed ID: 12623909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glatiramer: new preparation. No place in multiple sclerosis.
    Prescrire Int; 2004 Feb; 13(69):10-2. PubMed ID: 15055208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
    Su W; Kansal A; Vicente C; Deniz B; Sarda S
    J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition.
    Janković SM; Kostić M; Radosavljević M; Tesić D; Stefanović-Stoimenov N; Stevanović I; Raković S; Aleksić J; Folić M; Aleksić A; Mihajlović I; Biorac N; Borlja J; Vucković R
    Vojnosanit Pregl; 2009 Jul; 66(7):556-62. PubMed ID: 19678581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Update on current care guidelines: multiple sclerosis].
    Duodecim; 2013; 129(5):548-9. PubMed ID: 23520898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
    Chevalier J; Chamoux C; Hammès F; Chicoye A
    PLoS One; 2016; 11(3):e0150703. PubMed ID: 26987055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
    J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results].
    Arroyo E; Grau C; Ramo C; Parra J; Sánchez-Soliño O;
    Neurologia; 2010 Sep; 25(7):435-42. PubMed ID: 20964990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacy benefit forecast for a new interferon Beta-1a for the treatment of multiple sclerosis: development of a first-line decision tool for pharmacy-budget planning using administrative claims data.
    Meyer CM; Phipps R; Cooper D; Wright A
    J Manag Care Pharm; 2003; 9(2):168-74. PubMed ID: 14613346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate.
    Oleen-Burkey MA; Dor A; Castelli-Haley J; Lage MJ
    J Med Econ; 2011; 14(6):739-47. PubMed ID: 21913796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis].
    Elovaara I; Atula S; Erälinna JP; Färkkilä M; Pirttilä T; Remes A; Ruutiainen J; Varis T; ;
    Duodecim; 2010; 126(2):199-200. PubMed ID: 20405605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hass J, Firzlaff M (2005). Twenty-four-month comparison of immunomodulatory treatments--a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). European Journal of Neurology 12:425-431.
    Hasford J
    Eur J Neurol; 2005 Nov; 12(11):916-7; author reply 917. PubMed ID: 16241986
    [No Abstract]   [Full Text] [Related]  

  • 37. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K; Meyer K; Stafkey-Mailey D; Watson C
    J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glatiramer acetate for multiple sclerosis.
    Drug Ther Bull; 2001 Jun; 39(6):41-3. PubMed ID: 11432030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
    Bergvall N; Tambour M; Henriksson F; Fredrikson S
    J Med Econ; 2013; 16(3):349-57. PubMed ID: 23211038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.